NCT05199272
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 12 Years and older (Child, Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with uncontrolled or symptomatic CNS (central nervous system) metastases; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05199272